CHILDREN'S ALAWAY
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CHILDREN'S ALAWAY (CHILDREN'S ALAWAY).
Competitive antagonist of H1 histamine receptors, inhibiting histamine-mediated allergic responses; also blocks muscarinic acetylcholine receptors, contributing to anticholinergic effects.
| Metabolism | Hepatic metabolism via CYP3A4, CYP2D6, and other pathways; also undergoes N-demethylation and hydroxylation. |
| Excretion | Primarily renal (approx. 90%) as unchanged drug and glucuronide conjugates; minimal biliary/fecal elimination (<5%). |
| Half-life | Terminal elimination half-life 2.5–3.5 hours in children; prolonged in renal impairment or neonates. |
| Protein binding | 85–90% bound to albumin. |
| Volume of Distribution | 0.8–1.0 L/kg; distributes widely into tissues including CNS. |
| Bioavailability | Oral: 85–95%; Rectal: 80–90%. |
| Onset of Action | Oral: 30–60 minutes; Rectal: 20–30 minutes. |
| Duration of Action | 3–6 hours after single oral/rectal dose; may be shorter in febrile states. |
Children's Alaway (ketotifen fumarate ophthalmic solution) is approved for children aged 3 years and older. The typical dose is 1 drop in the affected eye(s) twice daily, approximately every 8-12 hours. There is no standard adult dose as the product is indicated only for pediatric use.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dosage adjustment required for renal impairment. Ketotifen is minimally absorbed systemically after ophthalmic administration. |
| Liver impairment | No dosage adjustment required for hepatic impairment. Systemic absorption is negligible. |
| Pediatric use | Children 3 years and older: 1 drop in the affected eye(s) twice daily. For children under 3 years, safety and efficacy not established. |
| Geriatric use | No specific geriatric dosing information provided. Use same dosing as for younger adults; however, elderly patients may be more sensitive to anticholinergic effects, though systemic absorption is low. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CHILDREN'S ALAWAY (CHILDREN'S ALAWAY).
| Breastfeeding | Diphenhydramine is excreted in breast milk in small amounts. M/P ratio not well defined. The AAP considers it compatible with breastfeeding, but may cause drowsiness in infants. Caution in preterm or neonates. |
| Teratogenic Risk | CHILDREN'S ALAWAY (diphenhydramine) is an antihistamine. In animal studies, no teratogenic effects at doses up to 5 times the human dose. Adequate human studies are lacking. First trimester: cautious use; some data suggest possible association with cleft palate. Second and third trimesters: generally considered low risk, but may cause uterine contractions or neonatal irritability near term. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to any component of the formulation","Neonates or premature infants","Narrow-angle glaucoma","Bladder neck obstruction or symptomatic prostatic hypertrophy","During an asthma attack","Concomitant use with MAO inhibitors","Lactation (due to risk of infant sedation and anticholinergic effects)"]
| Precautions | ["May cause drowsiness; avoid driving or operating machinery","Avoid use with other CNS depressants including alcohol","Use caution in patients with asthma, COPD, increased intraocular pressure, prostatic hyperplasia, or urinary retention","Do not exceed recommended dosage","Not for use in children under 2 years of age unless directed by a doctor","Do not use with MAO inhibitors"] |
| Food/Dietary | No clinically significant food interactions. No dietary restrictions required. |
Loading safety data…
| Fetal Monitoring | Monitor for excessive sedation in mother; fetal heart rate monitoring if used intravenously; neonatal observation for respiratory depression or irritability if used near delivery. |
| Fertility Effects | No known effect on human fertility. Animal studies at high doses showed no impairment of fertility. |
| Clinical Pearls | Children's Alaway (ketotifen fumarate ophthalmic solution 0.025%) is a mast cell stabilizer and antihistamine indicated for prophylaxis and treatment of allergic conjunctivitis. Onset of symptom relief typically within minutes. For maximal prophylactic effect, initiate treatment prior to allergen exposure. Do not administer while wearing contact lenses; remove lenses before use and wait at least 10 minutes before reinserting. Preservative benzalkonium chloride may be absorbed by soft contact lenses. Each vial contains no preservative; discard after single use if using unit-dose vials. May cause transient stinging or burning upon instillation. Efficacy may be reduced if patient is also using ocular corticosteroids concurrently. |
| Patient Advice | Wash hands before use. · Tilt head back, pull down lower eyelid, and instill one drop into the affected eye(s). · Avoid touching the dropper tip to any surface to prevent contamination. · Close eye gently and press finger to the inner corner of the eye for 1-2 minutes to reduce systemic absorption. · Do not use while wearing contact lenses; remove lenses before use and wait at least 10 minutes before reinserting. · Mild temporary stinging or burning may occur upon instillation. · If symptoms worsen or persist more than 72 hours, consult your healthcare provider. · Store at room temperature away from moisture and heat. · Discard any unused solution 1 month after opening the bottle (multidose) or immediately after use (unit-dose vials). · Keep out of reach of children. |